Core Insights - Company plans to select seven products, including Ceftriaxone Sodium Injection, in the national drug centralized procurement, which is expected to enhance its market share in core antibiotic products [1][2] - The sales revenue of these products is approximately 414 million yuan, accounting for 21.45% of the company's total revenue for the first three quarters of 2025 [1][2] - The procurement cycle is anticipated to run from the end of March 2026 to the end of December 2028 [2] Recent Events - On February 11, 2026, the company announced that its subsidiaries are set to be selected for the procurement of seven products, which will help consolidate its market position [2] - The company’s subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, which may provide tax benefits and policy support for three years [2] - As of January 30, 2026, the number of shareholders has slightly increased to 29,200, reflecting a 0.31% growth, with an average shareholding value rising by 1.68% [2] Stock Performance - Over the past week (February 6 to 12, 2026), the company's stock price fluctuated between 15.30 yuan and 15.29 yuan, with a slight overall decline and a price range fluctuation of 2.32% [3] - As of February 12, 2026, the stock price was 15.29 yuan, down 1.55%, underperforming the pharmaceutical and biotechnology sector, which fell by 0.60% [3] - Recent capital flow indicates a net outflow of major funds, with a net outflow of 8.5 million yuan on February 12, while small and medium-sized investments showed a net inflow, indicating higher retail investor participation [3]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national procurement bidding for expiring products, with seven products, including Cefotaxime Sodium Injection, expected to be selected, which could significantly impact the company's revenue [1] Group 1: Company Announcement - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, and its wholly-owned subsidiary, Jincheng Suzhi, are participating in the national procurement bidding for products whose agreements are expiring [1] - The seven products expected to be selected are projected to generate sales of 414 million yuan before the third quarter of 2025, accounting for 21.45% of the company's revenue [1] - The results of the selection are anticipated to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national centralized procurement for expiring drug agreements, with seven products, including Cefoperazone Sodium Injection and Ceftazidime Injection, expected to be selected for procurement [1] Group 1: Company Performance - The total sales revenue of the seven products expected to be selected for procurement in the first three quarters of 2025 is projected to be 414.46 million yuan, accounting for 21.45% of the company's total revenue during the same period [1] Group 2: Procurement Details - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., and its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd., participated in the bidding for the continuation procurement organized by the National Organization for the procurement of drugs whose agreements have expired [1] Group 1 - The company is involved in the bidding process for seven drug varieties, including Cefotaxime Sodium Injection and Ceftazidime Injection, as part of the national procurement program [1]